Bavarian Nordic (OTCMKTS:BVNRY) Sees Unusually-High Trading Volume – Time to Buy?

Bavarian Nordic (OTCMKTS:BVNRY) shares saw strong trading volume on Tuesday . 21,280 shares changed hands during trading, an increase of 730% from the previous session’s volume of 2,564 shares.The stock last traded at $9.9496 and had previously closed at $9.9360.

Bavarian Nordic Stock Up 0.1%

The company has a market cap of $2.37 billion, a price-to-earnings ratio of 11.31 and a beta of 1.27. The stock has a fifty day moving average price of $9.94 and a two-hundred day moving average price of $10.44.

Bavarian Nordic (OTCMKTS:BVNRY) last posted its earnings results on Thursday, March 12th. The company reported ($0.20) earnings per share for the quarter. Bavarian Nordic had a return on equity of 11.44% and a net margin of 22.20%.The firm had revenue of $226.16 million for the quarter. Analysts predict that Bavarian Nordic will post 0.67 earnings per share for the current fiscal year.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.